E1910 – A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among healthcare professionals and are NOT intended for use as patient educational materials.

  • Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.
  • Study Summary for Physicians: schema, study objectives, eligibility criteria, and other key information about the study.
  • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.

Mark Litzow MDE1910 Webinar: Mark R. Litzow, MD (Mayo Clinic), study chair, hosted a webinar in October 2014 for investigators and other research personnel interested in enrolling patients to this trial. Dr. Litzow provided an overview of the study and answered questions from participants at the conclusion of his presentation. (view Dr. Litzow’s bio). The webinar slides are posted on ECOG.org and CTSU.org (passwords required). Other inquiries about this webinar may be directed to the ECOG-ACRIN Clinical Education and Awareness Team via email.

Patient Educational Materials:

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.

  • Study Summary for Patients: study objectives, eligibility criteria, and a simplified schema in lay language to provide a more visual description of the trial to patients. [In Revision]
  • Testing Schedule for Patients: a patient-oriented guide that outlines the treatment steps in this trial, and focuses on the laboratory tests that will occur during the course of the trial. It includes blank fields for patients to fill in the dates of their testing procedures.

Information and Assistance from the National Cancer Institute:

  • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

Additional Information on ClinicalTrials.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit clinicaltrials.gov and search for record NCT02003222.